Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease.
Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease (CD).
The company announced that it had confirmed the similarity of its molecule to that of the reference product using an X-ray crystallography analysis of both primary amino acid sequence and 3-dimensional folding structure.
NeuClone is developing the proposed product with its partner, Serum Institute of India, and is scaling up to support a planned phase 1 trial of the biosimilar in 2019. Other biosimilars in the drug developer’s pipeline include trastuzumab (referencing Herceptin), which is slated to enter a phase 1 trial in 2018, and preclinical candidates for denosumab (referencing Prolia), palivizumab (referencing Synagis), and adalimumab (referencing Humira), and an additional 5 undisclosed products.
While the market for psoriasis treatments is heating up, with biologic competitors such as guselkumab (Tremfya) and ixekizumab (Taltz) vying for market share, Stelara’s most recently approved indication for the treatment of CD—which the FDA granted in September 2016 on the basis of positive data from 3 pivotal phase 3 studies—helps to buoy sales of the drug for Johnson & Johnson. In the treatment landscape for CD, the option to use an interleukin blocker provides an important alternative for patients who have not had an adequate response to treatment with an anti—tumor necrosis factor therapy.
On the strength of Stelara’s sales in all 3 indications, in its third-quarter 2017 earnings update, Johnson & Johnson, maker of the reference Stelara, reported $800 million in US sales for the quarter, up 42% from the same period in 2016, and $324 million in international sales, up 28.1%.
Another company that has disclosed its efforts to develop a biosimilar of the ustekinumab molecule is German drug maker Formycon, which, together with its partner Aristo Pharma, is in preclinical development with its candidate, FYB202.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.